Disease Report: Ulcerative colitis


Groups and Companies
Funding
Standard of Care
Unmet Medical Need
Novel Modalities and Combinations
Symptoms Evidence
Symptoms Targets
Pathogenesis Evidence
Pathogenesis Targets
Assays and Models

Certainly! Here is a comprehensive, up-to-date overview of funding agencies and opportunities for research and drug development in Ulcerative Colitis (UC), with sources and details as requested.

1. Summary:

Ulcerative colitis research and drug development are supported by a range of funding agencies, including major nonprofits, government bodies, and industry partners. The most active and significant funders are the Crohn’s & Colitis Foundation (USA), Crohn’s and Colitis Canada, Crohn’s & Colitis UK, the National Institutes of Health (NIH, USA), the Centers for Disease Control and Prevention (CDC, USA), and pharmaceutical companies such as Pfizer. Funding opportunities include research grants, fellowships, career development awards, and industry-sponsored competitive grant programs. Below is a detailed breakdown of agencies, current opportunities, and open calls as of May 2025.

2. Funding agencies:

Nonprofit Organizations

Government Agencies

Industry


3. Funding opportunities:

Crohn’s & Colitis Foundation (USA)

  • Research Fellowship Awards: For postdoctoral researchers in IBD, including UC. Up to $58,250/year for 1–3 years. Source
  • Career Development Awards: For early-career investigators transitioning to independence. Source
  • Senior Research Awards: For established investigators to generate preliminary data for larger grants. Source
  • Litwin IBD Pioneers: Supports innovative clinical and translational research. Source
  • IBD Ventures: Venture philanthropy program funding product development (including drugs) for IBD. Source

Crohn’s and Colitis Canada

  • Grants-in-Aid of Research (GIA): Up to $125,000/year for up to 3 years for UC research. Source
  • Innovations in IBD Research (INN): Up to $50,000 for novel or high-risk projects. Source
  • Fellowships and Partnerships: Co-funded with CIHR and other agencies. Source

Crohn’s & Colitis UK and Australia

NIH (USA)

  • R01, R21, K-series, and F-series grants: For basic, translational, and clinical research in UC. Source
  • NIDDK Clinical Trials: Funding for clinical studies in UC. Source

CDC (USA)

  • Epidemiology and Outcomes Research: Funding for studies on incidence, prevalence, and outcomes in UC. Source

Pfizer

  • Ulcerative Colitis Competitive Grant Program: Up to $150,000 (clinical) and $75,000 (translational) for UC research. Source

4. Open calls (as of May 2025):

  • Crohn’s & Colitis Foundation Research Fellowship Awards: Accepting applications for postdoctoral research in UC. Apply here
  • Crohn’s & Colitis Foundation Senior Research Awards: Open for established investigators. Apply here
  • Crohn’s and Colitis Canada Grants-in-Aid of Research: Annual competition open. Apply here
  • Pfizer Ulcerative Colitis Competitive Grant Program: Check for current RFPs and deadlines. Details
  • NIH/NIDDK Clinical Trials: Ongoing calls for clinical research in UC. ClinicalTrials.gov

5. Additional context:

  • Application Process: Most agencies require a detailed research proposal, CV, and institutional support letter. Deadlines and eligibility vary; always check the official website.
  • Eligibility: Varies by program; some are open internationally, others require US/Canada/UK affiliation.
  • Collaborative Funding: Many grants encourage or require collaboration between institutions or with industry partners.
  • Venture Philanthropy: Programs like IBD Ventures fund translational research and product development, bridging the gap between academia and industry.
  • Industry Partnerships: Pharma companies may offer investigator-initiated grants or partner with nonprofits for targeted research calls.

6. References:


If you need more details on a specific funding program or help with the application process, let me know!